Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTJOCTY)

• DTT Name: Tropomyosin receptor kinase (Trk)
• Gene Name: Trk
• DTT Type: Clinical trial target; [1]
• UniProt ID: NTRK1_HUMAN ; NTRK2_HUMAN ; NTRK3_HUMAN
• TTD ID: T25419
• KEGG Pathway:
  MAPK signaling pathway (hsa04010)
  Ras signaling pathway (hsa04014)
  Calcium signaling pathway (hsa04020)
  PI3K-Akt signaling pathway (hsa04151)
  Apoptosis (hsa04210)
  Neurotrophin signaling pathway (hsa04722)
  Inflammatory mediator regulation of TRP channels (hsa04750)
  Pathways in cancer (hsa05200)
  Transcriptional misregulation in cancer (hsa05202)
  Thyroid cancer (hsa05216)
  Central carbon metabolism in cancer (hsa05230)
• Reactome Pathway:
  Signalling to RAS (R-HSA-167044)
  Frs2-mediated activation (R-HSA-170968)
  ARMS-mediated activation (R-HSA-170984)
  Retrograde neurotrophin signalling (R-HSA-177504)
  NGF-independant TRKA activation (R-HSA-187024)
  TRKA activation by NGF (R-HSA-187042)
  Signalling to p38 via RIT and RIN (R-HSA-187706)
  PI3K/AKT activation (R-HSA-198203)
  Signalling to STAT3 (R-HSA-198745)
  PLC-gamma1 signalling (R-HSA-167021)

Molecular Interaction Atlas (MIA) of This DTT

1 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AB-106	DMEW62S	Non-small-cell lung cancer	2C25	Phase 2	[1]

References

• [1] Clinical pipeline report, company report or official report of AnHeart Therapeutics.